Formulated for prostate cancer to target androgen receptors and support hormone-responsive cell reduction.
Mechanism of Action
Flutamide competitively inhibits the uptake and binding of androgens at their target tissue receptors. It prevents the cellular actions of testosterone and dihydrotestosterone in the prostate.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
8–12 hours
Contraindications
Severe hepatic impairment, Hypersensitivity to flutamide
Severe Adverse Events
Hepatotoxicity, Methemoglobinemia, Interstitial lung disease — requires immediate medical attention
Common Side Effects
Hot flashes, Nausea, Anorexia
Uncommon Side Effects
Gynecomastia, Decreased libido, Diarrhea
Drug Interactions
Warfarin, Alcohol, Theophylline
Pregnancy Safety Warnings
FDA Category D: High risk of fetal feminization. Breastfeeding: Not applicable for primary indication.
Age Restrictions
Safety and efficacy in pediatric patients have not been established.
Information related to Eulexin is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
